ClinicalTrials.gg
CompletedNCT02318693Updated Aug 21, 2018Results posted

Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)

A Phase 4 interventional study of Sitagliptin and Glibenclamide in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-08-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
130th of 197
53 · median 102
Started
2015
with 12 others
Phase 4
68 of 198
3 open now
Registered
154th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 130th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2015, is one of 68 in phase 4, and was the 154th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This is a study of the efficacy of sitagliptin and glibenclamide in a short-term treatment on the glucose variability using continuous glucose monitoring (CGM) in Japanese participants with type 2 diabetes mellitus (T2DM). The primary hypothesis is that treatment with sitagliptin will be superior to treatment with glibenclamide in the change from baseline in mean amplitude of glycemic excursions (MAGE) through continuous glucose monitoring (CGM) after 13 days of treatment.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese participants with a diagnosis of Type 2 diabetes mellitus

Exclusion criteria

Exclusion Criteria:

  • History of Type 1 diabetes mellitus or ketoacidosis
  • History of insulin or thiazolidinedione (including fixed-dose drug combinations containing one of these drugs) in the 12 weeks before study participation
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Sitagliptin 50 mg

    Sitagliptin 50 mg administered orally once daily before breakfast for 14 days.

    Drug: Sitagliptin

  • Active comparator
    Glibenclamide 2.50 mg TDD

    Glibenclamide 1.25 mg administered orally twice daily (2.5 mg TDD) for 14 days. TDD = Total daily dose.

    Drug: Glibenclamide

Interventions

  • Sitagliptin 50 mg orally once a day before breakfast for 14 days

    Also known as: MK-0431

  • Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13

    MAGE is a popular metric for assessment of major (e.g., postprandial) glucose swings. MAGE is calculated as the average of differences between consecutive glucose peaks and nadirs greater than 1 standard deviation (SD) of 24-hour mean glucose. In this assessment, glucose levels were determined using continuous glucose monitoring (CGM) over 24 hours at Baseline and Day 13; CGM values were further corrected for blood glucose values obtained via participant-administered finger-stick. Least squares (LS) means values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

    Time frame: Baseline (Day -2) and Day 13

Secondary outcomes

  1. Change From Baseline in the Standard Deviation of Blood Glucose Levels

    SD is a popular metric for assessment of postprandial glucose swings. The SD of all glycemic excursions over 24 hours (i.e., total of 288 glucose values over 24 hours) was determined for Baseline and Day 13. Original values were obtained using CGM and corrected for blood glucose values obtained via participant-administered finger-stick. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

    Time frame: Baseline (Day -2) and Day 13

  2. Change From Baseline in Maximum Incremental Postprandial Glucose Levels in Each Meal

    The peak postprandial glucose level during the 3 hours post meal minus the preprandial glucose level 1 hour before meal was determined for corrected CGM values at Baseline and Day 13 for breakfast, lunch, and dinner. Meals were standardized with respect to total calories, and protein, fat, and carbohydrate composition as well as timing of administration. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates better control of postprandial glucose.

    Time frame: Baseline (Day -2) and Day 13

  3. Change From Baseline in 24-hour Mean Glucose Level

    The mean glucose level over 24-hours at Baseline and Day 13 was determined using CGM values corrected for participant-administered finger-stick values. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

    Time frame: Baseline (Day -2) and Day 13

  4. Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)

    Hypoglycemia, defined as low blood glucose, is a common side effect of medications used to treat diabetes mellitus type 2. The percentage of hypoglycemic corrected CGM readings (sensor glucose \<70, \<60, \<50 mg/dL) over a 24-hour period were determined at baseline and Day 13. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates improvement in occurrence of hypoglycemia.

    Time frame: Baseline (Day -2) and Day 13

07

Results

Posted Jan 23, 2017

Participant flow

Screening for study inclusion was performed over a 4-week period. Adults with type 2 diabetes were randomized into the study.

Participant flow — Overall Study
MilestoneSitagliptin 50 mgGlibenclamide 2.50 mg TDD
Started2627
Treated2626
Completed2626
Not completed01
Withdrew: Protocol violation01

Outcome measures

PrimaryChange From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13

MAGE is a popular metric for assessment of major (e.g., postprandial) glucose swings. MAGE is calculated as the average of differences between consecutive glucose peaks and nadirs greater than 1 standard deviation (SD) of 24-hour mean glucose. In this assessment, glucose levels were determined using continuous glucose monitoring (CGM) over 24 hours at Baseline and Day 13; CGM values were further corrected for blood glucose values obtained via participant-administered finger-stick. Least squares (LS) means values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

Time frame:
Baseline (Day -2) and Day 13
Reported as:
Least squares mean · mg/dL
Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13
mg/dLSitagliptin 50 mgGlibenclamide 2.50 mg TDD
Change From Baseline in Mean Amplitude of Glycemic Excursions (MAGE) at Day 13-18.5 (-30.0 to -7.1)-9.7 (-21.1 to 1.6)
Statistical analysis
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.245 · Ls means difference: -8.8 · 95% CI -23.8 to 6.2Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
SecondaryChange From Baseline in the Standard Deviation of Blood Glucose Levels

SD is a popular metric for assessment of postprandial glucose swings. The SD of all glycemic excursions over 24 hours (i.e., total of 288 glucose values over 24 hours) was determined for Baseline and Day 13. Original values were obtained using CGM and corrected for blood glucose values obtained via participant-administered finger-stick. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

Time frame:
Baseline (Day -2) and Day 13
Reported as:
Least squares mean · mg/dL
Change From Baseline in the Standard Deviation of Blood Glucose Levels
mg/dLSitagliptin 50 mgGlibenclamide 2.50 mg TDD
Change From Baseline in the Standard Deviation of Blood Glucose Levels-10.2 (-14.4 to -6.0)-4.2 (-8.4 to -0.1)
Statistical analysis
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.029 · Ls means difference: -5.9 · 95% CI -11.3 to -0.6Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
SecondaryChange From Baseline in Maximum Incremental Postprandial Glucose Levels in Each Meal

The peak postprandial glucose level during the 3 hours post meal minus the preprandial glucose level 1 hour before meal was determined for corrected CGM values at Baseline and Day 13 for breakfast, lunch, and dinner. Meals were standardized with respect to total calories, and protein, fat, and carbohydrate composition as well as timing of administration. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates better control of postprandial glucose.

Time frame:
Baseline (Day -2) and Day 13
Reported as:
Least squares mean · mg/dL
Change From Baseline in Maximum Incremental Postprandial Glucose Levels in Each Meal
mg/dLSitagliptin 50 mgGlibenclamide 2.50 mg TDD
Breakfast-24.8 (-34.1 to -15.6)-12.0 (-21.1 to -2.9)
Lunch-13.2 (-24.0 to -2.3)1.2 (-9.6 to 11.9)
Dinner-9.0 (-20.9 to 2.9)-14.1 (-25.9 to -2.3)
Statistical analysis
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.041 · Ls means difference: -12.8 · 95% CI -25.1 to -0.5Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.043 · Ls means difference: -14.3 · 95% CI -28.1 to -0.5Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.509 · Ls means difference: 5.1 · 95% CI -10.3 to 20.4Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
SecondaryChange From Baseline in 24-hour Mean Glucose Level

The mean glucose level over 24-hours at Baseline and Day 13 was determined using CGM values corrected for participant-administered finger-stick values. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from Baseline to Day 13 indicates improvement of the assessed outcome.

Time frame:
Baseline (Day -2) and Day 13
Reported as:
Least squares mean · mg/dL
Change From Baseline in 24-hour Mean Glucose Level
mg/dLSitagliptin 50 mgGlibenclamide 2.50 mg TDD
Change From Baseline in 24-hour Mean Glucose Level-19.1 (-28.5 to -9.7)-34.8 (-44.0 to -25.5)
Statistical analysis
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.020 · Ls means difference: 15.7 · 95% CI 2.5 to 28.8Model included terms for treatment, time and time-by-treatment interaction with a constraint that mean baseline is the same for both treatment groups.
SecondaryChange From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)

Hypoglycemia, defined as low blood glucose, is a common side effect of medications used to treat diabetes mellitus type 2. The percentage of hypoglycemic corrected CGM readings (sensor glucose \<70, \<60, \<50 mg/dL) over a 24-hour period were determined at baseline and Day 13. CGM values were corrected using a participant-administered finger-stick test for blood glucose. LS mean values were derived from a constrained longitudinal analysis model. A negative (-) change from baseline to Day 13 indicates improvement in occurrence of hypoglycemia.

Time frame:
Baseline (Day -2) and Day 13
Reported as:
Least squares mean · Percent change
Change From Baseline in Percentage of Hypoglycemic Values (Glucose Sensor Readings: < 70, <60, <50 mg/dL)
Percent changeSitagliptin 50 mgGlibenclamide 2.50 mg TDD
<70 mg/dL-0.3 (-1.6 to 1.0)0.8 (-0.5 to 2.1)
<60 mg/dL-0.4 (-1.3 to 0.5)0.2 (-0.7 to 1.1)
<50 mg/dL-0.3 (-0.8 to 0.2)-0.3 (-0.7 to 0.2)
Statistical analysis
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.134 · Ls means difference: -1.1 · 95% CI -2.5 to 0.3
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.226 · Ls means difference: -0.6 · 95% CI -1.5 to 0.4
  • Sitagliptin 50 mg vs Glibenclamide 2.50 mg TDD · constrained longitudinal analysis model · p = 0.332 · Ls means difference: 0.0 · 95% CI -0.1 to 0.0

Adverse events

Collected over Up to 4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 50 mg—0/26 (0%)11/26 (42.3%)
Glibenclamide 2.50 mg TDD—0/26 (0%)10/26 (38.5%)
Most frequent other events
Most frequent other events
EventSitagliptin 50 mgGlibenclamide 2.50 mg TDD
ErythemaSkin and subcutaneous tissue disorders10/266/26
HypoglycaemiaMetabolism and nutrition disorders2/263/26
PeriodontitisInfections and infestations2/260/26
Dermatitis ContactSkin and subcutaneous tissue disorders0/262/26
PruritisSkin and subcutaneous tissue disorders2/262/26

Baseline characteristics

Baseline data is provided for the Full Analysis Set (FAS) population consisting of all randomized participants who received at least one dose of study treatment, with at least one post-randomization/post-treatment observation for analysis, and with applicable baseline data.

Age, Continuous
Age, Continuous(Years)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Mean60.2 ± 8.459.5 ± 10.759.8 ± 9.5
Age, Customized
Age, Customized(Participants)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
<65 years151631
>=65 years111021
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Female011
Male262551
Body Weight
Body Weight(kg)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Mean70.2 ± 8.270.7 ± 11.270.5 ± 9.7
Height
Height(cm)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Mean169.5 ± 5.4169.3 ± 5.3169.4 ± 5.3
Body Mass Index
Body Mass Index(kg/m^2)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Mean24.4 ± 2.124.6 ± 3.024.5 ± 2.6
Duration of Diabetes Mellitus
Duration of Diabetes Mellitus(Years)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Mean6.4 ± 5.49.9 ± 5.58.2 ± 5.7
Smoking Status
Smoking Status(Participants)Sitagliptin 50 mgGlibenclamide 2.50 mg TDDTotal
Current Smoker8917
Ex-Smoker101020
Never Smoked8715

2 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Suzuki R, Eiki JI, Moritoyo T, Furihata K, Wakana A, Ohta Y, Tokita S, Kadowaki T. Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naive Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2018 Sep;20(9):2274-2281. doi: 10.1111/dom.13364. Epub 2018 Jun 11. PubMed 29770541 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Dec 2015, 10 months.

Results were first posted in Jan 2017, 1 year 1 month after primary completion.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 10 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 17, 2014
StartActual
Feb 4, 2015
Primary completionActual
Dec 15, 2015
CompletionActual
Dec 15, 2015
Results first posted
Jan 23, 2017
Last update
Aug 21, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02318693
Responsible party
Sponsor
First posted
Dec 17, 2014
Start date
Feb 4, 2015
Primary completion
Dec 15, 2015
Completion
Dec 15, 2015
Results posted
Jan 23, 2017
Last update
Aug 21, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion